121 related articles for article (PubMed ID: 15771456)
21. 3D-QSAR studies on sildenafil analogues, selective phosphodiesterase 5 inhibitors.
Yoo J; Thai KM; Kim DK; Lee JY; Park HJ
Bioorg Med Chem Lett; 2007 Aug; 17(15):4271-4. PubMed ID: 17553682
[TBL] [Abstract][Full Text] [Related]
22. The effect of DA-8159, a novel PDE5 inhibitor, on erectile function in the rat model of hypercholesterolemic erectile dysfunction.
Kang KK; Yu JY; Yoo M; Kwon JW
Int J Impot Res; 2005; 17(5):409-16. PubMed ID: 15920460
[TBL] [Abstract][Full Text] [Related]
23. Quinazolines as potent and highly selective PDE5 inhibitors as potential therapeutics for male erectile dysfunction.
Kim YH; Choi H; Lee J; Hwang IC; Moon SK; Kim SJ; Lee HW; Im DS; Lee SS; Ahn SK; Kim SW; Han CK; Yoon JH; Lee KJ; Choi NS
Bioorg Med Chem Lett; 2008 Dec; 18(23):6279-82. PubMed ID: 18976905
[TBL] [Abstract][Full Text] [Related]
24. Molecular modeling studies of pyridopurinone derivatives--potential phosphodiesterase 5 inhibitors.
Srivani P; Srinivas E; Raghu R; Sastry GN
J Mol Graph Model; 2007 Jul; 26(1):378-90. PubMed ID: 17307372
[TBL] [Abstract][Full Text] [Related]
25. 2-Phenylquinazolin-4(3H)-one, a class of potent PDE5 inhibitors with high selectivity versus PDE6.
Duan H; Zheng J; Lai Q; Liu Z; Tian G; Wang Z; Li J; Shen J
Bioorg Med Chem Lett; 2009 May; 19(10):2777-9. PubMed ID: 19375311
[TBL] [Abstract][Full Text] [Related]
26. Synthesis and SAR of tetracyclic pyrroloquinolones as phosphodiesterase 5 inhibitors.
Jiang W; Alford VC; Qiu Y; Bhattacharjee S; John TM; Haynes-Johnson D; Kraft PJ; Lundeen SG; Sui Z
Bioorg Med Chem; 2004 Mar; 12(6):1505-15. PubMed ID: 15018924
[TBL] [Abstract][Full Text] [Related]
27. Understanding the structure-activity and structure-selectivity correlation of cyclic guanine derivatives as phosphodiesterase-5 inhibitors by molecular docking, CoMFA and CoMSIA analyses.
Yang GF; Lu HT; Xiong Y; Zhan CG
Bioorg Med Chem; 2006 Mar; 14(5):1462-73. PubMed ID: 16263288
[TBL] [Abstract][Full Text] [Related]
28. Optimisation of PDE5 inhibitor therapy in men with erectile dysfunction: converting "non-responders" into "responders".
Eardley I
Eur Urol; 2006 Jul; 50(1):31-3. PubMed ID: 16517052
[No Abstract] [Full Text] [Related]
29. Microarray analysis of gene expression profile in the corpus cavernosum of hypercholesterolemic rats after chronic treatment with PDE5 inhibitor.
Jung HG; Shin JH; Kim KW; Yu JY; Kang KK; Ahn BO; Kwon JW; Yoo M
Life Sci; 2007 Jan; 80(7):699-708. PubMed ID: 17137605
[TBL] [Abstract][Full Text] [Related]
30. The role of pharmacokinetics and pharmacodynamics in phosphodiesterase-5 inhibitor therapy.
Mehrotra N; Gupta M; Kovar A; Meibohm B
Int J Impot Res; 2007; 19(3):253-64. PubMed ID: 16988721
[TBL] [Abstract][Full Text] [Related]
31. Combining testosterone and PDE5 inhibitors in erectile dysfunction: basic rationale and clinical evidences.
Greco EA; Spera G; Aversa A
Eur Urol; 2006 Nov; 50(5):940-7. PubMed ID: 16979814
[TBL] [Abstract][Full Text] [Related]
32. PDE5 inhibitors: An original access to novel potent arylated analogues of tadalafil.
Beghyn T; Hounsou C; Deprez BP
Bioorg Med Chem Lett; 2007 Feb; 17(3):789-92. PubMed ID: 17107795
[TBL] [Abstract][Full Text] [Related]
33. Phosphodiesterase type 5 inhibithors in older males.
Frajese GV; Pozzi F
J Endocrinol Invest; 2005; 28(11 Suppl Proceedings):112-5. PubMed ID: 16760638
[TBL] [Abstract][Full Text] [Related]
34. The clinical pharmacokinetics of phosphodiesterase-5 inhibitors for erectile dysfunction.
Gupta M; Kovar A; Meibohm B
J Clin Pharmacol; 2005 Sep; 45(9):987-1003. PubMed ID: 16100293
[TBL] [Abstract][Full Text] [Related]
35. [Experimental research of PDE5 activity in corpora cavernosa of ganyu qizhi rat model].
Chang D; Wang Z; Zhu B; Wang J; Zhang S; Hu Z
Zhonghua Nan Ke Xue; 2004 Jan; 10(1):71-3. PubMed ID: 14979214
[TBL] [Abstract][Full Text] [Related]
36. Comparison of different heterocyclic scaffolds as substrate analog PDE5 inhibitors.
Haning H; Niewöhner U; Schenke T; Lampe T; Hillisch A; Bischoff E
Bioorg Med Chem Lett; 2005 Sep; 15(17):3900-7. PubMed ID: 15993055
[TBL] [Abstract][Full Text] [Related]
37. The impact of the use of PDE5 inhibitors for erectile dysfunction on the lives of Australian men.
Matic H; McCabe MP
Int J Impot Res; 2007; 19(4):418-23. PubMed ID: 17538638
[TBL] [Abstract][Full Text] [Related]
38. A 46-amino acid segment in phosphodiesterase-5 GAF-B domain provides for high vardenafil potency over sildenafil and tadalafil and is involved in phosphodiesterase-5 dimerization.
Blount MA; Zoraghi R; Ke H; Bessay EP; Corbin JD; Francis SH
Mol Pharmacol; 2006 Nov; 70(5):1822-31. PubMed ID: 16926278
[TBL] [Abstract][Full Text] [Related]
39. Efficacy of PDE-5-inhibitors for erectile dysfunction. A comparative meta-analysis of fixed-dose regimen randomized controlled trials administering the International Index of Erectile Function in broad-spectrum populations.
Rosen RC; Shaw JW
Int J Impot Res; 2006; 18(6):570-1; author reply 572-3. PubMed ID: 17075585
[No Abstract] [Full Text] [Related]
40. Synthesis and pharmacological evaluations of sildenafil analogues for treatment of erectile dysfunction.
Flores Toque HA; Priviero FB; Teixeira CE; Perissutti E; Fiorino F; Severino B; Frecentese F; Lorenzetti R; Baracat JS; Santagada V; Caliendo G; Antunes E; De Nucci G
J Med Chem; 2008 May; 51(9):2807-15. PubMed ID: 18393409
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
